NCT02158507: Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting

Drug Category: Misc Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 19 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with more than two treatment regimens in the metastatic setting; Patients with prior use of anthracyclines and taxanes for metastatic disease or in the adjuvant or neoadjuvant setting; Patients with active symptomatic brain metastases that require treatment

Comments are closed.

Up ↑